Celldex Therapeutics, Inc. — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Celldex announced positive topline results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria. Both studies (1,939 patients randomized: 963 in CSU1, 976 in CSU2) met the primary endpoint of mean UAS7 change at Week 12 with both 150 mg Q4W and 300 mg Q8W doses showing highly significant improvements versus placebo (p<0.00001). Complete response rates (UAS7=0) reached 42-46% at Week 12 and 45-54% at Week 24 versus 9-18% placebo. In omalizumab-refractory patients, complete response rates were 41-55% at Week 12. The company plans BLA submission in 2027.
Why this rating
Positive Phase 3 data de-risks lead program; near-term path to BLA and potential revenue driver for $1.3B market-cap company. Material clinical validation but regulatory/commercial execution risks remain.
Price action (we called it positive)
before filing · preread $45.91 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.